BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21955663)

  • 1. Dose painting by contours versus dose painting by numbers for stage II/III lung cancer: practical implications of using a broad or sharp brush.
    Meijer G; Steenhuijsen J; Bal M; De Jaeger K; Schuring D; Theuws J
    Radiother Oncol; 2011 Sep; 100(3):396-401. PubMed ID: 21955663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of PET reconstruction algorithm and threshold on dose painting of non-small cell lung cancer.
    Knudtsen IS; van Elmpt W; Ollers M; Malinen E
    Radiother Oncol; 2014 Nov; 113(2):210-4. PubMed ID: 25443496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.
    van Der Wel A; Nijsten S; Hochstenbag M; Lamers R; Boersma L; Wanders R; Lutgens L; Zimny M; Bentzen SM; Wouters B; Lambin P; De Ruysscher D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):649-55. PubMed ID: 15708242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging.
    Wanet M; Delor A; Hanin FX; Ghaye B; Van Maanen A; Remouchamps V; Clermont C; Goossens S; Lee JA; Janssens G; Bol A; Geets X
    Strahlenther Onkol; 2017 Oct; 193(10):812-822. PubMed ID: 28733723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of tumour motion compensation and delineation methods on FDG PET-based dose painting plan quality for NSCLC radiation therapy.
    Thomas HM; Kinahan PE; Samuel JJE; Bowen SR
    J Med Imaging Radiat Oncol; 2018 Feb; 62(1):81-90. PubMed ID: 29193781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
    Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
    Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The use of PET/CT in radiotherapy of patients with non-small cell lung cancer].
    Lõcsei Z; Hideghéty K; Farkas R; Bellyei S; Sárosi V; Sebestyén K; Sebestyén Z; Kovács P; Mangel L
    Magy Onkol; 2011 Nov; 55(4):274-80. PubMed ID: 22128310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinical study of shrinking field radiation therapy based on (18)F-FDG PET/CT for stage III non-small cell lung cancer.
    Ding X; Li H; Wang Z; Huang W; Li B; Zang R; Sun H; Yi Y
    Technol Cancer Res Treat; 2013 Jun; 12(3):251-7. PubMed ID: 23289475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
    Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
    Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of [18F]fluorodeoxyglucose PET-CT staging on treatment planning in radiotherapy incorporating elective nodal irradiation for non-small-cell lung cancer: a prospective study.
    Kolodziejczyk M; Kepka L; Dziuk M; Zawadzka A; Szalus N; Gizewska A; Bujko K
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1008-14. PubMed ID: 20656419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer.
    Nestle U; Kremp S; Schaefer-Schuler A; Sebastian-Welsch C; Hellwig D; Rübe C; Kirsch CM
    J Nucl Med; 2005 Aug; 46(8):1342-8. PubMed ID: 16085592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probabilistic evaluation of target dose deterioration in dose painting by numbers for stage II/III lung cancer.
    Fontanarosa D; Witte M; Meijer G; Shakirin G; Steenhuijsen J; Schuring D; van Herk M; Lambin P
    Pract Radiat Oncol; 2015; 5(4):e375-82. PubMed ID: 25680996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.
    Ashamalla H; Rafla S; Parikh K; Mokhtar B; Goswami G; Kambam S; Abdel-Dayem H; Guirguis A; Ross P; Evola A
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1016-23. PubMed ID: 15979817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy.
    Lee E; Zeng J; Miyaoka RS; Saini J; Kinahan PE; Sandison GA; Wong T; Vesselle HJ; Rengan R; Bowen SR
    Med Phys; 2017 Jul; 44(7):3418-3429. PubMed ID: 28453861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A secondary analysis of FDG spatio-temporal consistency in the randomized phase II PET-boost trial in stage II-III NSCLC.
    La Fontaine M; Vogel W; van Diessen J; van Elmpt W; Reymen B; Persson G; Westman G; De Ruysscher D; Belderbos J; Sonke JJ
    Radiother Oncol; 2018 May; 127(2):259-266. PubMed ID: 29709378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer.
    van Elmpt W; De Ruysscher D; van der Salm A; Lakeman A; van der Stoep J; Emans D; Damen E; Öllers M; Sonke JJ; Belderbos J
    Radiother Oncol; 2012 Jul; 104(1):67-71. PubMed ID: 22483675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes.
    Even AJ; van der Stoep J; Zegers CM; Reymen B; Troost EG; Lambin P; van Elmpt W
    Radiother Oncol; 2015 Aug; 116(2):281-6. PubMed ID: 26238010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning.
    Hong R; Halama J; Bova D; Sethi A; Emami B
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):720-6. PubMed ID: 17293230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer.
    Schwarz M; Alber M; Lebesque JV; Mijnheer BJ; Damen EM
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):561-70. PubMed ID: 15890601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensity-modulated radiotherapy for locally advanced non-small-cell lung cancer: a dose-escalation planning study.
    Lievens Y; Nulens A; Gaber MA; Defraene G; De Wever W; Stroobants S; Van den Heuvel F;
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):306-13. PubMed ID: 20888706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.